Alpine Global Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Alpine Global Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-43,281	Closed	-$125K	–	787
2021 Q4	$125K	Buy	+43,281	New	+$160K	0.02%	600
2017 Q2	–	Sell	-10,402	Closed	-$209K	–	333
2017 Q1	$209K	Buy	+10,402	New	+$207K	0.05%	266
2016 Q3	–	Sell	-16,491	Closed	-$113K	–	176
2016 Q2	$113K	Buy	+16,491	New	+$138K	0.05%	122

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Alpine Global Management's ZYNE Position: Q1 2022 in Review

Alpine Global Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2022, closing a stake of 43,281 shares — an estimated $125K sold.

Alpine Global Management first reported a position in ZYNE in Q2 2016 and held it in 3 quarters. The position peaked at $209K in Q1 2017. 59 funds tracked by Wall St. Rank hold ZYNE as of Q1 2022.

Alpine Global Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2022 after selling out during the quarter.
Alpine Global Management sold 43,281 Zynerba Pharmaceuticals, Inc shares in Q1 2022, an estimated $125K.
Alpine Global Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2016 and held it in 3 quarters.
Alpine Global Management's Zynerba Pharmaceuticals, Inc position peaked at $209K in Q1 2017.
59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.